Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

Aya Shiba‐Ishii(University of Tsukuba), Aaron N. Hata(Harvard University)
bioRxiv (Cold Spring Harbor Laboratory)
July 16, 2021
Cited by 2


Related Papers